BG108179A - Pyridazinone aldose reductase inhibitors - Google Patents

Pyridazinone aldose reductase inhibitors

Info

Publication number: BG108179A
Authority: BG; Bulgaria
Prior art keywords: diabetic; inhibitors; aldose reductase; relates; compositions
Prior art date: 2001-03-30

Application number

BG108179A

Other languages

Bulgarian (bg)

English (en)

Inventor

Banavara L. Mylari

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2003-09-17

Publication date

2004-09-30

2003-09-17 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-09-30 Publication of BG108179A publication Critical patent/BG108179A/xx

Links

239000003288 aldose reductase inhibitor Substances 0.000 title abstract 3
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title abstract 2
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 3
229940118148 Aldose reductase inhibitor Drugs 0.000 abstract 2
208000002249 Diabetes Complications Diseases 0.000 abstract 2
206010012655 Diabetic complications Diseases 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
-1 3-hydroxy-3-methylglutaryl Chemical group 0.000 abstract 1
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 1
102000016912 Aldehyde Reductase Human genes 0.000 abstract 1
108010053754 Aldehyde reductase Proteins 0.000 abstract 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
102100038509 E3 ubiquitin-protein ligase ARIH1 Human genes 0.000 abstract 1
229930091371 Fructose Natural products 0.000 abstract 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
239000005715 Fructose Substances 0.000 abstract 1
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 1
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 1
102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract 1
229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000002220 antihypertensive agent Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000009101 diabetic angiopathy Diseases 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
230000010030 glucose lowering effect Effects 0.000 abstract 1
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 abstract 1
108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
239000000600 sorbitol Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BG108179A 2001-03-30 2003-09-17 Pyridazinone aldose reductase inhibitors BG108179A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (fr)	2001-03-30	2002-01-31	Inhibiteurs pyridazinone d'aldose réductase

Publications (1)

Publication Number	Publication Date
BG108179A true BG108179A (en)	2004-09-30

Family

ID=23071435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108179A BG108179A (en)	2001-03-30	2003-09-17	Pyridazinone aldose reductase inhibitors

Country Status (43)

Country	Link
US (2)	US6579879B2 (fr)
EP (3)	EP1491541B1 (fr)
JP (1)	JP2004528319A (fr)
KR (1)	KR100586138B1 (fr)
CN (1)	CN1215067C (fr)
AP (1)	AP2002002461A0 (fr)
AR (1)	AR035798A1 (fr)
AT (3)	ATE348100T1 (fr)
AU (1)	AU2002226634B2 (fr)
BG (1)	BG108179A (fr)
BR (1)	BR0208571A (fr)
CA (1)	CA2442476A1 (fr)
CZ (1)	CZ20032563A3 (fr)
DE (3)	DE60202452C5 (fr)
DK (2)	DK1373259T3 (fr)
EA (1)	EA006023B1 (fr)
EC (1)	ECSP034671A (fr)
EE (1)	EE200300470A (fr)
ES (2)	ES2231681T3 (fr)
GE (1)	GEP20053675B (fr)
HR (1)	HRP20030752A2 (fr)
HU (1)	HUP0303644A3 (fr)
IL (1)	IL156462A0 (fr)
IS (3)	IS2205B (fr)
MA (1)	MA27003A1 (fr)
MX (1)	MXPA03008850A (fr)
MY (1)	MY134304A (fr)
NO (1)	NO20034345L (fr)
NZ (1)	NZ528406A (fr)
OA (1)	OA12453A (fr)
PA (1)	PA8541801A1 (fr)
PE (1)	PE20030007A1 (fr)
PL (1)	PL365294A1 (fr)
PT (2)	PT1491540E (fr)
SI (1)	SI1373259T1 (fr)
SK (1)	SK11852003A3 (fr)
TN (1)	TNSN02037A1 (fr)
TW (1)	TWI245762B (fr)
UA (1)	UA73236C2 (fr)
UY (1)	UY27237A1 (fr)
WO (1)	WO2002079198A1 (fr)
YU (1)	YU71403A (fr)
ZA (1)	ZA200304671B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001876A (en)	1996-07-24	1999-12-14	Warner-Lambert Company	Isobutylgaba and its derivatives for the treatment of pain
ES2240657T3 (es) *	2001-02-28	2005-10-16	Pfizer Products Inc.	Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
ATE348100T1 (de) *	2001-03-30	2007-01-15	Pfizer Prod Inc	Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
CN1269814C (zh)	2002-01-09	2006-08-16	辉瑞产品公司	哒嗪酮抗糖尿病药的制备方法和中间体
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CA2568640C (fr)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Composition pharmaceutique contenant de l'irbesartan
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035251A1 (en) *	2004-06-30	2006-02-16	Whitehead Institute For Biomedical Research	Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
BRPI0706523A2 (pt) *	2006-01-13	2011-01-04	Wyeth Corp	composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
CL2007001873A1 (es) *	2006-06-27	2008-01-04	Takeda Pharmaceutical	Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
JP5498168B2 (ja)	2006-12-01	2014-05-21	ブリストル−マイヤーズスクイブカンパニー	アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2008116107A2 (fr) *	2007-03-21	2008-09-25	Takeda San Diego, Inc.	Activateurs de glucokinase
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
EP2509596B1 (fr)	2009-12-08	2019-08-28	Case Western Reserve University	Gamma acides aminés pour le traitement de troubles oculaires
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
CA2848877A1 (fr) *	2011-09-15	2013-03-21	Taipei Medical University	Utilisation d'indolyl et d'hydroxamates d'indolinyl pour le traitement d'une defaillance cardiaque ou d'une lesion neuronale
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
SG11201507496UA (en)	2013-04-17	2015-11-27	Pfizer	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
JP2018511616A (ja) *	2015-04-14	2018-04-26	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物および方法
WO2017168174A1 (fr)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	Nouvelles formes pharmaceutiques du sildénafil
IL283809B2 (en)	2016-06-21	2024-01-01	Univ Columbia	Compounds for use in a method of treating neuropathy, retinopathy, nephropathy, or cardiomyopathy
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
EP3548035A4 (fr)	2016-11-30	2020-07-22	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
AU2018215678A1 (en)	2017-02-06	2019-08-22	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
IL272246B2 (en)	2017-07-28	2026-01-01	Applied Therapeutics Inc	History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
IL321451A (en)	2018-11-21	2025-08-01	Univ Case Western Reserve	Compositions and methods of modulating short-chain dehydrogenase activity
US11248001B2 (en)	2019-01-18	2022-02-15	Astrazeneca Ab	PCSK9 inhibitors and methods of use thereof
AU2020254610A1 (en)	2019-04-01	2021-11-18	Applied Therapeutics Inc.	Inhibitors of aldose reductase
CN113966396A (zh)	2019-05-07	2022-01-21	迈阿密大学	遗传性神经病和相关障碍的治疗和检测
US11274082B2 (en)	2019-05-31	2022-03-15	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2020243423A1 (fr)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
MX2022010258A (es)	2020-02-21	2023-01-24	Univ Case Western Reserve	Composiciones y métodos para tratar la lesión renal.
WO2022120353A1 (fr) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) *	1990-11-30	1993-12-01	Tsumura & Co.	Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
CZ387092A3 (en)	1991-03-28	1994-02-16	Pfizer	Pyridazinoacetic acids, their derivatives, process of their preparation and use
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
TR200000764T2 (tr) *	1997-09-24	2001-03-21	Orion Corporation	Fosfolamban inhibitörleri olarak, 1-okza, aza ve tiyanaftalin-2-on'ların biseterleri.
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
ATE348100T1 (de) *	2001-03-30	2007-01-15	Pfizer Prod Inc	Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
AU2002236131B2 (en) *	2001-04-30	2005-04-14	Pfizer Products Inc.	Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
CN1269814C (zh) *	2002-01-09	2006-08-16	辉瑞产品公司	哒嗪酮抗糖尿病药的制备方法和中间体

2002
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/fr not_active Abandoned
- 2002-01-31 EP EP04023150A patent/EP1491541B1/fr not_active Expired - Lifetime
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 EP EP02716247A patent/EP1373259B1/fr not_active Expired - Lifetime
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/fr not_active Expired - Lifetime
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/fr not_active Ceased
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active Expired - Fee Related
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2006
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown

Also Published As

Publication number	Publication date
HUP0303644A2 (hu)	2004-03-01
ZA200304671B (en)	2004-06-25
TWI245762B (en)	2005-12-21
EP1491541A1 (fr)	2004-12-29
KR100586138B1 (ko)	2006-06-07
MY134304A (en)	2007-12-31
DK1373259T3 (da)	2005-03-29
PT1491540E (pt)	2007-01-31
CZ20032563A3 (cs)	2004-05-12
YU71403A (sh)	2006-05-25
NO20034345D0 (no)	2003-09-29
DE60217930T2 (de)	2007-10-18
HK1061678A1 (en)	2004-09-30
WO2002079198A1 (fr)	2002-10-10
MA27003A1 (fr)	2004-12-20
IS8251A (is)	2006-01-23
HUP0303644A3 (en)	2008-06-30
EA006023B1 (ru)	2005-08-25
UY27237A1 (es)	2002-12-31
US6579879B2 (en)	2003-06-17
UA73236C2 (en)	2005-06-15
ES2274369T3 (es)	2007-05-16
IL156462A0 (en)	2004-01-04
NZ528406A (en)	2004-03-26
ATE348100T1 (de)	2007-01-15
MXPA03008850A (es)	2003-12-04
EP1373259B1 (fr)	2004-12-29
CN1500087A (zh)	2004-05-26
SK11852003A3 (sk)	2004-07-07
KR20030088484A (ko)	2003-11-19
ATE286049T1 (de)	2005-01-15
PL365294A1 (en)	2004-12-27
EP1491540A1 (fr)	2004-12-29
NO20034345L (no)	2003-09-29
DE60202452D1 (de)	2005-02-03
PT1373259E (pt)	2005-03-31
AU2002226634B2 (en)	2007-01-25
GEP20053675B (en)	2005-11-25
CA2442476A1 (fr)	2002-10-10
HRP20030752A2 (en)	2005-06-30
DK1491540T3 (da)	2007-03-26
PA8541801A1 (es)	2002-10-28
US6849629B2 (en)	2005-02-01
PE20030007A1 (es)	2003-01-28
ATE352551T1 (de)	2007-02-15
DE60216823T2 (de)	2007-10-04
EP1491541B1 (fr)	2007-01-24
IS2205B (is)	2007-02-15
TNSN02037A1 (fr)	2005-12-23
EP1491540B1 (fr)	2006-12-13
SI1373259T1 (en)	2005-04-30
US20030162784A1 (en)	2003-08-28
AP2002002461A0 (en)	2002-06-30
DE60216823D1 (de)	2007-01-25
BR0208571A (pt)	2004-03-23
EE200300470A (et)	2004-02-16
IS8250A (is)	2006-01-23
DE60202452C5 (de)	2006-11-23
EA200300673A1 (ru)	2003-12-25
OA12453A (en)	2006-05-24
US20020143017A1 (en)	2002-10-03
JP2004528319A (ja)	2004-09-16
ECSP034671A (es)	2003-08-29
EP1373259A1 (fr)	2004-01-02
AR035798A1 (es)	2004-07-14
ES2231681T3 (es)	2005-05-16
CN1215067C (zh)	2005-08-17
IS6845A (is)	2003-06-16
DE60217930D1 (de)	2007-03-15
DE60202452T2 (de)	2006-02-09

Publication	Publication Date	Title
MY134304A (en)	2007-12-31	Pyridazinone aldose reductase inhibitors.
MY115288A (en)	2003-05-31	Substituted pyrimidines for control of diabetic complications.
DE60309836D1 (de)	2007-01-04	Kristalline zeolithische aluminosilikat-zusammensetzung: uzm-9
EP4242655A3 (fr)	2024-02-21	Procédés et compositions pour le traitement du cancer et d'infections pérsistantes en inhibant la voie de la mort céllulaire programmée (pd-1)
WO2005123672A3 (fr)	2006-03-02	Inhibiteurs de kinase
UA86962C2 (en)	2009-06-10	Viral polymerase inhibitors
ZA200609088B (en)	2008-08-27	Flame-retardants
MX2007006084A (es)	2007-07-11	Composiciones y metodos de recubrimiento.
NO20081581L (no)	2008-05-23	Polymorfer av benzoatsalt av 2-[[6-[(3R)-3-amino-l-piperldinyl]-3,4-dihydro-3-metyl-2,4-diokso- 1(2H)-pyrlmidinylJmetyl)benzonitril, og fremgangsmater for anvendelse derav
WO2006062984A3 (fr)	2006-08-31	Inhibiteurs de proteines kinases
MY136039A (en)	2008-08-29	Sorbitol dehydrogenase inhibitors
WO2004020599A3 (fr)	2006-12-28	Antagonistes de la voie hedgehog, methodes et applications correspondantes
PL360434A1 (en)	2004-09-06	N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives
WO2005097701A3 (fr)	2006-04-13	Liant hydraulique
MX2023009045A (es)	2023-08-10	Derivados novedosos de pirimidin-2-il sulfonamida.
WO2006055831A3 (fr)	2006-12-07	Inhibiteurs de kinase
WO2006103277A3 (fr)	2006-12-28	Piperidines substituees
BRPI0512547A (pt)	2008-03-25	pirimidinas
WO2006028963A3 (fr)	2006-11-09	Composes heterocycliques substitues et leurs utilisations
BRPI0502564A (pt)	2006-02-07	Composições de aditivo e de combustìvel, uso de um componente estabilizante, e, método para melhorar a estabilidade de uma composição de aditivo de combustìvel ou de uma composição de combustìvel
MXPA06000986A (es)	2006-04-11	Compuestos.
EP1247809A3 (fr)	2003-12-17	Dérivés de triazine et leur application comme inhibiteurs de sorbitol-déhydrogénase
WO2007014008A3 (fr)	2007-07-12	Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
MX2007004893A (es)	2007-06-14	Metodos y composiciones para el tratamiento de leucemia linfocitica cronica.
WO2005079390A3 (fr)	2006-12-14	Inhibition de la signalisation du fgf